PMC:7696151 / 62575-62853
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1819 | 27-30 | Chemical | denotes | HCQ | MESH:D006886 |
| 1820 | 242-245 | Chemical | denotes | ROS | MESH:D017382 |
| 1830 | 157-162 | Disease | denotes | tumor | MESH:D009369 |
| 1831 | 187-199 | Disease | denotes | inflammation | MESH:D007249 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T112 | 157-162 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T401 | 0-278 | Sentence | denotes | The therapeutic effects of HCQ may be attributed to the significant inhibition of pro-tumorigenic and pro-inflammatory cytokines, which not only limited the tumor progression by reducing inflammation of lamina propria, but also decreased the ROS production in macrophages [111]. |